SKIN ATLAS · ACTIVE INGREDIENT · 4 MIN READ

Cat's Claw Extract: Pentacyclic Oxindole Alkaloids for Fibroblast Activation

Cat's claw extract in cosmetics refers to a plant extract obtained from the South American vine Uncaria tomentosa, containing pentacyclic oxindole alkaloids (POAs) as its primary active compounds. These alkaloids target dermal fibroblasts and are associated in scientific literature with effects on cell proliferation, collagen synthesis, and anti-inflammatory signaling pathways. The extract is considered a bioactive phytochemical with a broad spectrum of activity in connective tissue.

Term and Origin

The common name "cat's claw" derives from the Spanish Uña de Gato and describes the hook-shaped thorns of the climbing plant Uncaria tomentosa from the Rubiaceae family. The vine is native to the rainforests of the Amazon basin—primarily in Peru, Bolivia, and Ecuador—and can reach lengths of up to 30 meters. In the traditional medicine of the indigenous peoples of Peru, including the Asháninka, a bark and root decoction of U. tomentosa had been used for centuries as an anti-inflammatory and immunomodulatory remedy.

The scientific systematization of its constituents began in the 1970s, when Austrian and Peruvian research groups isolated the first alkaloids from the bark extract. For cosmetic use, it is crucial to distinguish between two chemotypes: plants containing predominantly pentacyclic oxindole alkaloids (POA chemotype) and those containing tetracyclic oxindole alkaloids (TOA chemotype). Only the POA chemotype is relevant for dermal application, as TOAs can competitively inhibit the biological activity of the POA fraction. Standardized extracts for cosmetics must therefore be analytically standardized for POA content and depleted of TOAs.

Phytochemically, the POA fraction primarily contains the alkaloids isopteropodine (isomitraphylline), pteropodine, speciophyllin, uncarin F, and mitraphylline—structurally related oxindole derivatives with a common pentacyclic core structure. The extract also contains procyanidins, cinnamic acid derivatives (particularly chlorogenic acid), and phytosterols as secondary active components.

Characteristics & Mechanism of Action

The primary target of pentacyclic oxindole alkaloids in the dermal context is fibroblasts—the cells primarily responsible for the biosynthesis of type I and III collagen, as well as glycosaminoglycans such as hyaluronic acid. In vitro studies show that POA-rich extracts can increase the proliferation rate of human skin fibroblasts and positively influence the transcription of collagen-coding genes (COL1A1, COL3A1). At the molecular level, modulation of the NF-κB signaling pathway is discussed: POAs inhibit the nuclear translocation of NF-κB, thereby reducing the expression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), which are known to negatively regulate fibroblast activity and collagen turnover.

In parallel, the extract is attributed with antioxidant capacity, largely provided by the procyanidin fraction and phenolic carboxylic acid derivatives (chlorogenic acid, caffeic acid). These components scavenge reactive oxygen species (ROS), thereby indirectly protecting the fibroblast matrix from oxidative degradation—a mechanism closely linked to the concept of oxidative stress in the skin. An inhibition of matrix metalloproteinases MMP-1 and MMP-3—both collagen-degrading enzymes—is also reported, acting through ROS-dependent and ROS-independent pathways.

In the context of oil mists—that is, oil-based spray formulations—the solubility of the alkaloids is a critical formulation parameter. As basic nitrogen compounds, POAs are more soluble in polar systems than in pure lipid phases. Stable oil mist formulations therefore often use hydroalcoholic extract pre-solutions or sufficiently polar cosolvents (e.g., propylene glycol, glycerin) at a high enough concentration to distribute the alkaloids homogeneously in the dispersed phase. Encapsulation in biopolymer matrices is another formulation approach that touches on encapsulation technology.

Skincare Approach

In applied cosmetics, cat's claw extract is incorporated into formulations aimed at connective tissue support, skin structure, and anti-inflammatory effects. Concentrations between 0.5% and 3% (based on standardized dry extract) are described in scientific literature; the actually effective concentration depends heavily on the POA content of the extract used, which can range from 0.5% to 4% POA depending on standardization. The concentration stated on the final product is therefore only meaningfully interpretable in conjunction with the standardization level of the extract.

In the context of layering, it should be considered that cat's claw extract can be used in both aqueous formulations and oil phases—depending on the extract type—due to its partially amphiphilic active ingredient matrix. In combination with ceramides, it can complement the barrier effect without interfering with their mechanism of action. The timing of application is playing an increasingly discussed role: fibroblast activity is subject to circadian fluctuations, which theoretically makes the chronobiological integration of active ingredients such as POAs into day and night routines relevant—a context systematically addressed by the chronobiology of the skin.

For use in combination with other bioactive phytochemicals—such as bakuchiol or AHAs—no known incompatibility has been described. However, when using acid preparations simultaneously, it should be noted that highly acidic environments can potentially protonate the alkaloids, thereby influencing their skin penetration. From a formulation perspective, a pH range of 4.5 to 6.5 is stated as stable for most POA-containing applications. Those who wish to explore the topic of formulation vs. pure active ingredient list further will find relevant contextual information there.

As part of the NATURFACTOR® approach—The Science of Rhythm—the chronobiological logic of the routine is given greater weight than individual active ingredient hits. In the Day Rhythm, the Porcelain Skin Serum takes on the active role of moisture retention, barrier function, and skin structure—with pullulan, two forms of hyaluronic acid, Kigelia extract (bioactive flavonoids), amino acid-based active ingredients, functional silk polypeptides, and licorice root extract. The Blue Crystal Drops face oil is assigned to the Night Rhythm and combines bioactive phytosterols, vitamin C, bisabolol, as well as essential oils from blue lotus and blue cornflower for nighttime regeneration, antioxidant protection, and a protective care film. Since cat's claw extract is not one of the active ingredients contained in these products, it is recommended to look at the overarching chronobiology of the skin logic for its integration into a complete routine. Both products are also available together as The Perfect Duo—serum for the day, face oil for the night.

Realistic Expectations

The available data on cat's claw extract in topical skincare is based mostly on in vitro studies and a few controlled human studies. The transferability of cell culture experiments to the complex in vivo situation of the skin is limited: fibroblasts in cell culture react more strongly to extracts, among other reasons, because they do not have to be penetrated through an intact epidermis and stratum corneum. The actual dermal bioavailability of the alkaloids after topical application has so far been insufficiently characterized.

Those starting with a POA-containing formulation should realistically plan for an observation period of eight to twelve weeks before effects on skin structure and elasticity become measurable—similar to other fibroblast-stimulating approaches. Individual variation is considerable: skin type, age (older skin fibroblasts may respond differently to stimuli than younger ones), the baseline condition of the barrier, and the formulation quality of the product used significantly influence the result. Clinical endpoints such as skin elasticity (measured by cutometer), wrinkle volume (by fringe projection), or collagen density (by high-frequency ultrasound) provide more objective statements than purely subjective perception.

Allergic reactions to Uncaria tomentosa extracts are rare but documented—primarily in individuals with known hypersensitivity to plants from the Rubiaceae family. A patch test before first use is recommended for sensitive or reactive skin. Interactions with topical medications have not been systematically investigated; in the case of active dermatological treatment, consultation with the treating physician should be sought.

Frequently Asked Questions

What distinguishes pentacyclic from tetracyclic oxindole alkaloids in cat's claw extracts?

Pentacyclic oxindole alkaloids (POAs) and tetracyclic oxindole alkaloids (TOAs) are structurally related but functionally different compounds. TOAs can competitively inhibit the immunomodulatory and cell-proliferative effects of POAs by competing for the same receptor binding sites. For dermal cosmetics, only POA-rich, TOA-depleted extracts are relevant. Standardized quality extracts analytically verify the POA content and guarantee a TOA content below a defined limit.

Can cat's claw extract actually build collagen?

In vitro, increased collagen synthesis through fibroblast stimulation by POA-containing extracts is well documented. In vivo—that is, with topical application to human skin—the data is significantly thinner, as the penetration depth of the alkaloids through the skin barrier is limited. The extract supports the cellular environment that promotes collagen synthesis—however, direct collagen formation through topical application is not equivalent to the direct incorporation of collagen molecules. More precisely stated: POAs can modulate fibroblast-activating signals, which can benefit the body's own collagen synthesis.

Is cat's claw extract suitable for sensitive skin?

Cat's claw extract generally shows a favorable tolerance profile and is not classified in scientific literature as primarily irritating. The anti-inflammatory component (NF-κB inhibition, cytokine reduction) can even be beneficial for reactive skin. Nevertheless: every botanical extract theoretically carries sensitization potential. In the case of known plant allergies, active dermatitis, or rosacea, a dermatological assessment before use as well as a patch test on the forearm over 48 hours is recommended.

Conclusion

Cat's claw extract—precisely: a TOA-depleted, standardized extract of Uncaria tomentosa standardized for pentacyclic oxindole alkaloids—is a scientifically interesting phytochemical with well-characterized fibroblast-stimulating and anti-inflammatory properties in vitro. The transition to clinical efficacy in topical formulations remains subject to strict formulation requirements: degree of standardization, penetration enhancers, pH stability, and the question of bioavailability after percutaneous absorption are crucial variables. In daily skincare, the extract should be sensibly integrated into a structured rhythm that takes into account barrier stability and the circadian requirements of the skin—no single active ingredient replaces a consistent skincare approach tailored to biological rhythms.

1. Sandoval M, Okuhama NN, Zhang XJ, Lorenzana LF, Condezo LA, Lao J, Miller MJS. (2002). Anti-inflammatory and antioxidant activities of cat's claw (Uncaria tomentosa and Uncaria guianensis) are independent of their alkaloid content. Phytomedicine, 9(4), 325–337.
2. Dreifuss AA, Bastos-Pereira AL, Ávila TV, Soley BS, Rivero AJ, Aguilar JL, Acco A. (2010). Antitumoral and antioxidant effects of a hydroalcoholic extract of cat's claw (Uncaria tomentosa) in an in vivo carcinosarcoma model. Journal of Ethnopharmacology, 130(1), 127–133.
3. Pilarski R, Zielinski H, Ciesiołka D, Gulewicz K. (2006). Antioxidant activity of ethanolic and aqueous extracts of Uncaria tomentosa (Willd.) DC. Journal of Ethnopharmacology, 104(1–2), 18–23.
4. Wurm M, Kacani L, Laus G, Keplinger K, Dierich MP. (1998). Pentacyclic oxindole alkaloids from Uncaria tomentosa induce human endothelial cells to release a lymphocyte-proliferation-regulating factor. Planta Medica, 64(8), 701–704.
5. Erowele GI, Kalejaiye AO. (2009). Pharmacology and therapeutic uses of cat's claw. American Journal of Health-System Pharmacy, 66(11), 992–995.